Codexis Interest Expense 2011-2025 | CDXS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Codexis

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-10.4 M	-12.3 M	124 K	1.15 M	-156 K	-656 K	-291 K	-92 K	-94 K	-	-	13 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.15 M	-12.3 M	-2.27 M

Quarterly Interest Expense Codexis

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-1.29 M	-984 K	-942 K	-	-4.92 M	-985 K	-516 K	-	-3.9 M	-9 K	-25 K	-	216 K	-63 K	-3 K	-	983 K	23 K	-88 K	-	-50 K	13 K	-86 K	-	-403 K	-88 K	-125 K	-	-80 K	-82 K	-60 K	-	-68 K	-34 K	22 K	-	7 K	-49 K	3 K	-	-26 K	-96 K	-25 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
983 K	-4.92 M	-416 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Aclaris Therapeutics ACRS	2.95 M	$ 3.04	0.33 %	$ 235 M	USA
Aptevo Therapeutics APVO	472 K	$ 0.55	-10.18 %	$ 152 K	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.09	-2.68 %	$ 7.43 B	Australia
Autolus Therapeutics plc AUTL	9.29 M	$ 1.8	7.9 %	$ 459 M	Britain
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
BioVie BIVI	4.3 M	$ 1.22	1.05 %	$ 1.8 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 209.89	0.44 %	$ 5 B	Danmark
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.18	-14.31 %	$ 392 M	Israel
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Catalyst Biosciences CBIO	1.04 M	$ 12.24	-0.93 %	$ 806 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 27.02	-0.37 %	$ 1.31 B	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Certara CERT	-15.5 M	$ 8.83	-0.67 %	$ 1.42 B	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Cellectis S.A. CLLS	371 K	$ 4.91	3.37 %	$ 116 M	France
Axon Enterprise AXON	286 M	$ 580.12	-0.64 %	$ 43.9 B	USA
Aytu BioScience AYTU	-512 K	$ 2.47	0.82 %	$ 15.5 M	USA
ChromaDex Corporation CDXC	3 K	-	-0.88 %	$ 598 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA